The effect of systemic erythropoietin and oral prednisolone on recent-onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial.

摘要: Background To evaluate the effect of systemic erythropoietin, as well oral steroids, in management recent-onset non-arteritic anterior ischemic optic neuropathy (NAION). Method Patients diagnosed with NAION within 5 days were randomized into group A (systemic erythropoietin), B (oral steroids), and C (control). Group received 10,000 units erythropoietin twice a day for 3 days. prednisone 75 mg daily tapered off 6 weeks. Results The mean best-corrected visual acuity (± SD) at time presentation was 1 ± 0.56, 1.01 0.6, 0.94 0.47 logMAR groups A, B, C, respectively (P = 0.140); corresponding values 6-month follow-up 0.70 0.44, 0.73 0.35, 0.75 0.39 logMAR, 0.597). Fifty-five percent patients versus 34.3% 31.2% had an improvement least lines 6th month visit 0.04). Peripapillary retinal nerve fiber layers 189 58, 193 64, 199 62 micrometers, 0.779), which decreased to 88 12, 74 25, 71 18, 0.041). Conclusion findings our study indicate beneficial effects preserving function structure NAION. Trial registration Clinical number: IR.SBMU.ORC.REC.1397.18.